GPR43 (G protein-coupled receptor 43) is a recently discovered short-chain free fatty acid receptor which plays important role in adipogenesis. Here we explored the transcriptional expression rule of GPR43 in porcine adipose tissue and primary cultured adipocytes. Partial cDNA of GPR43 was successfully cloned from swine by RT-PCR and the expression profile of GPR43 mRNA was studied from different types, different growing stages, and different sites of porcine adipose tissue as well as porcine primary cultured adipocytes. The results showed that porcine GPR43 shared high homology with human (89%), mouse (84%) and rat (83%). The expression level of GPR43 mRNA was significantly higher in adipose tissue of obese pigs than that of lean pigs, and also the expression level gradually increased with age. Further, the abundance of GPR43 mRNA level was higher in subcutaneous fat than in visceral fat. In addition, during the adipocytes differentiation, the expression of GPR43 mRNA increased in a time-dependent manner. These data indicated that GPR43 gene expression was relate to the site of adipose tissue, economic type, and age of pig as well as differentiating state of adipocytes, implying that GPR43 can be a potential factor to regulate adipogenesis.
Adipocytes ; cytology ; metabolism ; Adipose Tissue ; metabolism ; Animals ; Cells, Cultured ; DNA, Complementary ; biosynthesis ; genetics ; Gene Expression Profiling ; Humans ; RNA, Messenger ; biosynthesis ; genetics ; Receptors, Cell Surface ; biosynthesis ; genetics ; Receptors, G-Protein-Coupled ; biosynthesis ; genetics ; Swine ; Transcription, Genetic

Objective To evaluate the efficacy and safety of neurokinin1 (NK1) receptor antagonist aprepitant combined with prednisone and tropisetron in prevention of nausea and vomiting (CINV) induced by R-CHOP or CHOP regimen. Methods A total of 90 patients with diffuse large B-cell lymphoma (DLBCL) who accepted R-CHOP or CHOP regimen in the People''s Hospital of Tianjin from October 2015 to January 2016 were divided into aprepitant group (45 cases) and the control group (45 cases) according to the random number table. In aprepitant group, day 1: aprepitant 125 mg 1 h before chemotherapy, prednison 100 mg, tropisetron 10 mg, and tropisetron 5 mg 2 hours after chemotherapy;day 2-3:aprepitant 80 mg and prednison 100 mg, tropisetron 10 mg; day 4-5: prednison 100 mg. In the control group, day 1: prednison 100 mg 1 h before chemotherapy, tropisetron 10 mg, and tropisetron 5 mg 2 h after chemotherapy; days 2-3: prednison 100 mg, tropisetron 10 mg; day 4-5: prednison 100 mg. Data on nausea, vomiting and remission treatment were collected every day. The complete remission (CR) rates of CINV without vomiting and remission drugs in the whole cycle were recorded. Functional living index-emesis questionnaire (FILE) was used to assess the effect of CINV on the life quality of the patients. Results CR in aprepitant group was higher than that in the control group (77.8 ％ vs. 55.6 ％, χ2= 5.000, P= 0.025). The rate of no vomiting in aprepitant regimen was higher than that in the control regimen (82.2 ％ vs. 62.2 ％, χ2 = 4.486, P= 0.034). The average scores of FILE between the two groups were (113 ±10) and (100 ±11) scores respectively, and there was a significant difference (t=12.437, P<0.001). The related adverse reactions of vomiting-stopping drugs in both groups had no statistical difference. Conclusion The aprepitant combined with tropisetron and prednisone can improve effectively nausea and vomiting induced by R-CHOP or CHOP chemotherapy regimen for DLBCL patients.